On Thursday, DMK Pharmaceuticals Corporation (DMK) experienced a significant increase in share price, with a 17% rise, following an announcement that the company has regained full rights to commercialize ZIMHI (naloxone).
DMK is trading on the Nasdaq at $0.70, up 18.67% or $0.11 per share. It has traded between $0.45 and $21.70 in the past 52-week period.
This comes after the termination of an exclusive commercialization and distribution agreement with US WorldMeds, LLC. As a result, DMK is now actively pursuing commercialization opportunities for ZIMHI in the United States, Canada, and Europe, with a focus on generating new and near-term revenues.
ZIMHI is primarily targeted toward first responders in the United States, although the company is exploring additional opportunities for commercialization in other markets as well.
With full control over the commercialization and distribution of ZIMHI, DMK is well-positioned to capitalize on the growing demand for this life-saving medication, which is used to quickly reverse the effects of fentanyl (opioid) overdose.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.